vs

Side-by-side financial comparison of GCL Global Holdings Ltd (GCL) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $98.7M, roughly 1.5× GCL Global Holdings Ltd). GCL Global Holdings Ltd runs the higher net margin — -5.2% vs -5.5%, a 0.4% gap on every dollar of revenue. Tarsus Pharmaceuticals, Inc. produced more free cash flow last quarter ($13.0M vs $-5.2M).

GCL Global Holdings Ltd is a leading clean energy enterprise focusing on R&D, production and operation of photovoltaic products, energy storage systems and low-carbon energy solutions. Its main markets cover Asia, Europe, North America, serving utility, commercial and residential distributed energy users across the globe.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

GCL vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.5× larger
TARS
$151.7M
$98.7M
GCL
Higher net margin
GCL
GCL
0.4% more per $
GCL
-5.2%
-5.5%
TARS
More free cash flow
TARS
TARS
$18.2M more FCF
TARS
$13.0M
$-5.2M
GCL

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
GCL
GCL
TARS
TARS
Revenue
$98.7M
$151.7M
Net Profit
$-5.1M
$-8.4M
Gross Margin
11.0%
Operating Margin
-6.7%
-5.3%
Net Margin
-5.2%
-5.5%
Revenue YoY
128.4%
Net Profit YoY
63.8%
EPS (diluted)
$-0.04
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GCL
GCL
TARS
TARS
Q4 25
$151.7M
Q3 25
$98.7M
$118.7M
Q2 25
$142.1M
$102.7M
Q1 25
$78.3M
Q4 24
$66.4M
Q3 24
$36.1M
$48.1M
Q2 24
$40.8M
Q1 24
$27.6M
Net Profit
GCL
GCL
TARS
TARS
Q4 25
$-8.4M
Q3 25
$-5.1M
$-12.6M
Q2 25
$5.6M
$-20.3M
Q1 25
$-25.1M
Q4 24
$-23.1M
Q3 24
$-1.9M
$-23.4M
Q2 24
$-33.3M
Q1 24
$-35.7M
Gross Margin
GCL
GCL
TARS
TARS
Q4 25
Q3 25
11.0%
Q2 25
15.0%
Q1 25
Q4 24
Q3 24
16.2%
Q2 24
Q1 24
Operating Margin
GCL
GCL
TARS
TARS
Q4 25
-5.3%
Q3 25
-6.7%
-12.2%
Q2 25
2.3%
-21.6%
Q1 25
-33.5%
Q4 24
-36.8%
Q3 24
-5.6%
-52.3%
Q2 24
-81.6%
Q1 24
-136.5%
Net Margin
GCL
GCL
TARS
TARS
Q4 25
-5.5%
Q3 25
-5.2%
-10.6%
Q2 25
3.9%
-19.8%
Q1 25
-32.1%
Q4 24
-34.8%
Q3 24
-5.2%
-48.7%
Q2 24
-81.6%
Q1 24
-129.4%
EPS (diluted)
GCL
GCL
TARS
TARS
Q4 25
$-0.17
Q3 25
$-0.04
$-0.30
Q2 25
$0.05
$-0.48
Q1 25
$-0.64
Q4 24
$-0.57
Q3 24
$-0.61
Q2 24
$-0.88
Q1 24
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GCL
GCL
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$16.6M
$417.3M
Total DebtLower is stronger
$52.0M
$72.4M
Stockholders' EquityBook value
$33.1M
$343.4M
Total Assets
$159.9M
$562.2M
Debt / EquityLower = less leverage
1.57×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GCL
GCL
TARS
TARS
Q4 25
$417.3M
Q3 25
$16.6M
$401.8M
Q2 25
$18.2M
$381.1M
Q1 25
$407.9M
Q4 24
$291.4M
Q3 24
$2.7M
$317.0M
Q2 24
$323.6M
Q1 24
$298.5M
Total Debt
GCL
GCL
TARS
TARS
Q4 25
$72.4M
Q3 25
$52.0M
$72.3M
Q2 25
$11.9M
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
GCL
GCL
TARS
TARS
Q4 25
$343.4M
Q3 25
$33.1M
$335.1M
Q2 25
$35.9M
$332.6M
Q1 25
$342.5M
Q4 24
$224.5M
Q3 24
$15.9M
$237.5M
Q2 24
$252.2M
Q1 24
$275.2M
Total Assets
GCL
GCL
TARS
TARS
Q4 25
$562.2M
Q3 25
$159.9M
$534.6M
Q2 25
$101.6M
$495.0M
Q1 25
$500.8M
Q4 24
$377.0M
Q3 24
$49.6M
$376.3M
Q2 24
$376.8M
Q1 24
$349.3M
Debt / Equity
GCL
GCL
TARS
TARS
Q4 25
0.21×
Q3 25
1.57×
0.22×
Q2 25
0.33×
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GCL
GCL
TARS
TARS
Operating Cash FlowLast quarter
$-4.8M
$19.3M
Free Cash FlowOCF − Capex
$-5.2M
$13.0M
FCF MarginFCF / Revenue
-5.3%
8.6%
Capex IntensityCapex / Revenue
0.4%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GCL
GCL
TARS
TARS
Q4 25
$19.3M
Q3 25
$-4.8M
$18.3M
Q2 25
$-10.3M
$-29.4M
Q1 25
$-20.7M
Q4 24
$-22.2M
Q3 24
$6.1M
$-8.7M
Q2 24
$-14.4M
Q1 24
$-37.8M
Free Cash Flow
GCL
GCL
TARS
TARS
Q4 25
$13.0M
Q3 25
$-5.2M
$16.3M
Q2 25
$-10.5M
$-30.4M
Q1 25
$-21.2M
Q4 24
$-22.3M
Q3 24
$-8.9M
Q2 24
$-15.4M
Q1 24
$-38.0M
FCF Margin
GCL
GCL
TARS
TARS
Q4 25
8.6%
Q3 25
-5.3%
13.8%
Q2 25
-7.4%
-29.6%
Q1 25
-27.1%
Q4 24
-33.5%
Q3 24
-18.6%
Q2 24
-37.8%
Q1 24
-137.5%
Capex Intensity
GCL
GCL
TARS
TARS
Q4 25
4.2%
Q3 25
0.4%
1.6%
Q2 25
0.1%
1.0%
Q1 25
0.8%
Q4 24
0.1%
Q3 24
0.6%
Q2 24
2.5%
Q1 24
0.6%
Cash Conversion
GCL
GCL
TARS
TARS
Q4 25
Q3 25
Q2 25
-1.84×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons